CAS · 149647-78-9
Product Overview
Vorinostat is a high-purity a-api supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.
Product Specifications
| Appearance | A white to orange crystalline or crystalline powder |
|---|---|
| Melting point | 157.0~161.0°C |
| Identification | 1. Max. absorption is in the wavelength 242nm 2. The infrared absorption is same as reference |
| Impurity A | 0.15% max |
| Impurity D | 0.15% max |
| Individual impurity | 0.1% max |
| Total impurity | 0.5% max |
| Methanol | 0.3% max |
| Ethanol | 0.5% max |
| Loss on drying | 0.5% max |
| Residue on ignition | 0.1% max |
| Heavy metals | 0.001% max |
| Chlorides | 0.02% max |
| Assay (on dried base) | 98.5% min |
Applications
Vorinostat is a pharmaceutical compound primarily used as a histone deacetylase (HDAC) inhibitor in cancer therapy. It is applied in the treatment of cutaneous T-cell lymphoma (CTCL) and is under investigation for other hematologic and solid tumors. In research, Vorinostat serves as a tool for studying epigenetic regulation, gene expression, and the role of HDACs in disease pathways. It is also utilized in preclinical studies to explore combination therapies, investigate mechanisms of drug resistance, and develop novel therapeutic strategies targeting epigenetic modifications.
Benefits
The benefits of Vorinostat lie in its ability to modulate gene expression by inhibiting histone deacetylase activity, leading to cell cycle arrest, apoptosis, and differentiation of malignant cells. Clinically, it offers therapeutic efficacy in patients with refractory or advanced CTCL, improving disease control and quality of life. Its targeted mechanism reduces off-target toxicity compared to conventional chemotherapies. In research, Vorinostat provides insights into epigenetic regulation and aids in the development of new HDAC-targeted therapies, supporting precision medicine approaches.
Conclusion
Vorinostat is a significant epigenetic therapy agent with applications in cancer treatment and biomedical research. Its HDAC inhibitory activity enables effective modulation of gene expression, providing clinical benefits in CTCL and advancing understanding of epigenetic mechanisms. By supporting both therapeutic intervention and scientific investigation, Vorinostat continues to be an important compound in oncology and translational research.
Previous
Next